Direct answer
There is no credible human clinical evidence establishing that Fadogia agrestis raises testosterone, improves libido or enhances performance. The available safety literature is largely animal-based and includes testicular, liver and kidney toxicity signals, which should be treated as reasons for caution rather than as proof of human harm.
The central task is to match the claim to the actual human evidence. For Fadogia agrestis, that means separating traditional use, biological mechanisms, animal research, small clinical studies and higher-quality human trials. These are not equivalent forms of evidence. The current evidence label for this page is Insufficient human efficacy evidence / Safety concern, and the discussion below keeps that boundary visible.
What Fadogia agrestis is
No credible human clinical efficacy trial was identified in the Stage 2 search for testosterone, libido or performance outcomes.
Product identity matters because botanical ingredients can vary by plant part, species, extraction method, standardization, purification and dose. A study using one preparation should not automatically be used to support another product with a different composition.
Human evidence gap
A 28-day rat study reported adverse changes in indices of testicular function after aqueous stem extract administration.
The strongest practical question is not whether a mechanism sounds plausible. It is whether appropriately designed human research measured a meaningful outcome, whether the population resembles the intended user, and whether the commercial product resembles the studied intervention.
Why animal efficacy claims do not transfer
Another rat study reported evidence consistent with hepatic and renal cellular toxicity/oxidative injury.
Where trials are small, short, old, population-specific or formulation-specific, the conclusion should remain narrow. A positive signal in one group does not establish a general benefit in healthy adults. Equally, a lack of efficacy in one preparation should not automatically prove that every possible preparation is ineffective.
Evidence quality and interpretation
Evidence quality depends on more than whether a study is randomized. Sample size, blinding, trial duration, participant characteristics, outcome selection and the exact tested preparation all matter. Botanical studies also face extra challenges such as species identification, extract standardization and batch-to-batch variability.
This is particularly important for ingredients marketed for testosterone, prostate health, libido, cognition or stress. These topics often use outcomes that can be influenced by age, baseline health, medication use, sleep, diet, psychological factors and underlying disease. A supplement study should not be treated as a substitute for evaluation of those factors.
Dose, preparation and label matching
A studied dose is context, not a personalized recommendation. The useful comparison is whether a product clearly states:
- the exact ingredient identity;
- the plant part or material used;
- extract ratio or standardized constituent, where relevant;
- dose per serving;
- number of servings required;
- purification or contaminant-testing information where relevant;
- other active ingredients that could influence the claimed outcome.
If those details are missing, the evidence match becomes weaker.
Safety and interactions
Safety is especially important when a supplement contains pharmacologically active constituents, has contamination concerns, or is marketed for symptoms that could reflect an underlying medical condition. People using prescription medicines, people with cardiovascular or neurological conditions, and those with unexplained urinary, sexual, cognitive or hormonal symptoms should not assume that a botanical supplement is automatically low risk.
For some ingredients, the safety issue is not only the herb itself but also product identity and quality. Purification, heavy-metal testing, adulteration controls, plant-part verification and standardized manufacturing can materially affect risk.
What this evidence does not show
This page does not treat manufacturer claims, category popularity, traditional use or animal findings as proof of clinical benefit. It also does not infer that a product works because it contains an ingredient that has been studied in another preparation or population.
The evidence may still be useful. A weak or preliminary evidence base can help identify which claims are overstated, which product details matter, and where caution is warranted.
Practical decision framework
A useful way to evaluate Fadogia agrestis is:
- define the outcome being claimed;
- identify whether credible human evidence exists for that exact outcome;
- check whether the participant population matches the intended user;
- confirm that the tested preparation resembles the product label;
- review safety, contamination and interaction concerns;
- avoid using the supplement as a substitute for appropriate medical evaluation where symptoms are persistent or clinically significant.
The MenPS links on this page are for product-category discovery. They do not change the evidence grade.
FAQs
Are there human trials of Fadogia?
The current evidence is best described as insufficient human efficacy evidence / safety concern. The answer depends on the exact preparation, population and outcome.
Does Fadogia raise testosterone in humans?
The human evidence is limited enough that broad claims should be avoided. The most relevant studies are summarized above.
What did animal studies show?
Preparation matters because botanical extracts, powders, oils, purified products and standardized extracts may not be equivalent.
Are liver or kidney concerns established in humans?
A studied dose can provide context, but it is not an individualized dosing recommendation.
Should animal toxicity signals affect supplement decisions?
Safety depends on product quality, medication use, medical history and the pharmacology of the ingredient.
Claim controls carried forward from Stage 2
- Do not make testosterone, libido or performance claims from animal studies.
- State clearly that absence of credible human efficacy evidence is a central finding.
- Give animal toxicity signals appropriate prominence while avoiding direct prediction of human harm.
Authoritative sources
- PubMed-indexed human/clinical literature: https://pubmed.ncbi.nlm.nih.gov/18023305/
- PubMed-indexed human/clinical literature: https://pubmed.ncbi.nlm.nih.gov/19755438/
Why this distinction matters
For this ingredient, the safest interpretation is the narrowest one supported by the cited human evidence. Broader marketing language should be treated as a hypothesis unless comparable clinical research directly supports the same preparation, population and outcome.
- Do not make testosterone, libido or performance claims from animal studies.
- State clearly that absence of credible human efficacy evidence is a central finding.
- Give animal toxicity signals appropriate prominence while avoiding direct prediction of human harm.